Development of a safe dexamethasone-eluting electrode array for cochlear implantation.

Area of Science:

• Oto-neurology
• Biomaterials Science
• Surgical Innovation

Background:

• Cochlear implantation can cause trauma, leading to hearing loss.
• Intratympanic dexamethasone is used to mitigate surgical trauma and preserve residual hearing.
• This study investigates dexamethasone elution from intracochlear arrays in vivo.

Purpose of the Study:

• To evaluate the safety and efficacy of dexamethasone eluted from intracochlear electrode arrays.
• To assess the impact of dexamethasone elution on cochlear tissue response and hearing preservation.
• To compare different iterations of dexamethasone-eluting arrays (DX1, DX2, DX3) against control arrays.

Main Methods:

• Three trials were conducted in adult guinea pigs with dexamethasone-eluting or control intracochlear arrays.
• Animals were monitored for 90 days with hearing tests at multiple time points.
• Histological analysis assessed spiral ganglion neuron density, organ of Corti integrity, and tissue response (fibrosis, ossification).

Main Results:

• No significant differences in spiral ganglion neuron density, organ of Corti condition, or fibrosis/ossification between dexamethasone and control groups.
• Cochleostomy seals formed in all implanted cochleae.
• DX2 arrays showed reduced hearing loss and improved spiral ganglion neuron survival compared to controls, potentially linked to elution differences.

Conclusions:

• Dexamethasone delivered via intracochlear arrays is safe in the guinea pig cochlea at the tested doses.
• Dexamethasone elution did not impede cochleostomy seal formation.
• Hearing protection efficacy depends on dexamethasone elution levels and surgical trauma intensity.